Table 2.
Summary of studies reporting on the incidence and prevalence of primary Sjögren’s
| Incidence | |||
|---|---|---|---|
| Study | Geography | Incidence | Incidence metric |
| Izmirly 2019 [23] | United States (US) | 3.5 | per 100,000 person-years |
| Pillemer 2001 [26]d | US | 3.9 | per 100,000 person-years |
| Seror 2021 [27] | France | 0.3–4.1 | per 100,000 persons |
| Nannini 2013 [25] | US | 5.1 | per 100,000 persons |
| Maciel 2017 [24] | US | 5.8 | per 100,000 persons |
| Crowson 2011 [22]d | US | 3.9 | per 100,000 persons |
| Avina-Zubieta 2017 [21] | Canada | 26.1 | per 100,000 personsa |
| Prevalence | ||||||
|---|---|---|---|---|---|---|
| Study | Geography | Prevalence | Prevalence metric | Point or period prevalence | Study population size | Female (%) |
| Cortes 2019 [28] | Spain | 55.0 | per 100,000 personsb | Point | Not reported (NR) | NR |
| Devauchelle-Pensec 2019 [30] | France | 29.5 | per 100,000 persons | Period 2005–2016 | NR | 90% |
| Izmirly 2019 [23] | US | 12.4/13.1e | per 100,000 person-years | Period January 2007–December 2007 | 1,585,873 | NR |
| Maciel 2017 [31] | US | 103.0f | per 100,000 personsb | Point 1st January 2015 | 113,306 | 86% |
| Narvaez 2020 [32] | Spain | 250.0 | per 100,000 personsc | Period November 2016–October 2017 | 4,916 | NR |
| Seror 2021 [27] | France | 22–32 | per 100,000 persons | Period 2011–2018 | NR | 76–89% |
| Tsuboi 2014 [29] | Japan | 30.0 | per 100,000 personsc | Period January 2010–December2010 | NRg | NR |
| Valim 2013 [33] | Brazil | 170.0 | per 100,000 personsc | Point | 1,205 | 51% |
| Zhang 1995 [34] | China | 330.0–770.0 | per 100,000 personsc | NR | NR | NR |
NR not reported, US United States
To allow for comparison between studies, prevalence estimates were scaled to 100,000 persons:
aThis study reported 1175 incident cases in a Canadian population of 4,500,000 people and therefore incidence was manually calculated to allow for comparison
bThese studies reported prevalence per 10,000 population and estimates were multiplied by 10
cThese studies reported prevalence as a percentage and estimates were multiplied by 1000
dPillemer 2001 and Crowson 2011 both reported on data collected as part of the Rochester Epidemiology Project, during the same time frame, and therefore likely contain some patient overlap
eIzmirly 2019 reported a prevalence of 12.4 (unadjusted) and 13.1 (age-adjusted to the US population in 2000)
fThe prevalence in Maciel 2017 was age- and sex-adjusted to the US White population in 2010
gTsuboi 2014 did not report a total population size from which the authors identified cases of primary Sjögren’s. Instead, the authors report the prevalence of primary Sjögren’s, extrapolated over the whole population of Japan (October 1, 2021)